Red Door Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$699K Sell
14,577
-408
-3% -$17.5K 0.06% 151
2026
Q1
$551K Buy
14,985
+392
+3% +$18.6K 0.06% 160
2025
Q4
$742K Sell
14,593
-101
-0.7% -$5.17K 0.08% 128
2025
Q3
$815K Buy
14,694
+5,186
+55% +$304K 0.09% 112
2025
Q2
$656K Sell
9,508
-100
-1% -$6.8K 0.08% 134
2025
Q1
$667K Hold
9,608
0.1% 113
2024
Q4
$826K Buy
9,608
+6,013
+167% +$650K 0.13% 104
2024
Q3
$428K Buy
3,595
+199
+6% +$26.5K 0.07% 141
2024
Q2
$485K Hold
3,396
0.09% 118
2024
Q1
$436K Sell
3,396
-496
-13% -$59K 0.08% 128
2023
Q4
$403K Buy
3,892
+136
+4% +$13.4K 0.09% 127
2023
Q3
$342K Buy
3,756
+806
+27% +$71K 0.09% 133
2023
Q2
$239K Buy
+2,950
New +$241K 0.05% 203
2021
Q3
Sell
-10
Closed 454
2021
Q2
$0 Buy
+10
New +$388 ﹤0.01% 646
2020
Q3
Sell
-140
Closed -$4K 305
2020
Q2
$4K Hold
140
﹤0.01% 385
2020
Q1
$4K Buy
+140
New +$4.17K ﹤0.01% 362

Other funds holding NVO

Red Door Wealth Management's NVO Position: Q2 2026 in Review

Red Door Wealth Management reduced its Novo Nordisk (NVO) stake by 2.7% in Q2 2026, selling an estimated $17.5K and leaving 14,577 shares worth $699K. The position accounts for 0.06% of the portfolio, ranked #151.

Red Door Wealth Management first reported a position in NVO in Q1 2020 and has held it in 16 quarters since. The position peaked at $826K in Q4 2024. 654 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Red Door Wealth Management held 14,577 shares of Novo Nordisk worth $699K as of Q2 2026.
  • Red Door Wealth Management sold 408 Novo Nordisk shares in Q2 2026, an estimated $17.5K.
  • Novo Nordisk made up 0.06% of Red Door Wealth Management's portfolio in Q2 2026, its #151 holding.
  • Red Door Wealth Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 16 quarters since.
  • Red Door Wealth Management's Novo Nordisk position peaked at $826K in Q4 2024.
  • 654 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Red Door Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.